DiaMedica Therapeutics Inc. – NASDAQ:DMAC

DiaMedica Therapeutics stock price today

$6.17
+0.75
+14.05%
Financial Health
0
1
2
3
4
5
6
7
8
9

DiaMedica Therapeutics stock price monthly change

+55.91%
month

DiaMedica Therapeutics stock price quarterly change

+55.91%
quarter

DiaMedica Therapeutics stock price yearly change

+87.20%
year

DiaMedica Therapeutics key metrics

Market Cap
229.41M
Enterprise value
38.57M
P/E
-3.06
EV/Sales
N/A
EV/EBITDA
-2.83
Price/Sales
N/A
Price/Book
1.34
PEG ratio
-0.15
EPS
-0.56
Revenue
N/A
EBITDA
-26.04M
Income
-19.26M
Revenue Q/Q
N/A
Revenue Y/Y
34549.43%
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

DiaMedica Therapeutics stock price history

DiaMedica Therapeutics stock forecast

DiaMedica Therapeutics financial statements

DiaMedica Therapeutics Inc. (NASDAQ:DMAC): Profit margin
Jun 2023 0 -4.47M
Sep 2023 0 -4.47M
Dec 2023 30.83M -5.16M -16.74%
Mar 2024 0 -5.15M
DiaMedica Therapeutics Inc. (NASDAQ:DMAC): Analyst Estimates
Sep 2025 0 -10.24M
Oct 2025 0 -10.24M
Dec 2025 0 -8.72M
Dec 2025 0 -7.97M
  • Analysts Price target

  • Financials & Ratios estimates

DiaMedica Therapeutics Inc. (NASDAQ:DMAC): Debt to assets
Jun 2023 62050000 2.30M 3.72%
Sep 2023 58139000 2.51M 4.32%
Dec 2023 54160000 3.10M 5.73%
Mar 2024 49260000 2.91M 5.91%
DiaMedica Therapeutics Inc. (NASDAQ:DMAC): Cash Flow
Jun 2023 -5.03M -28.12M 36.85M
Sep 2023 -4.79M 1.19M -6K
Dec 2023 -3.57M 6.39M -489.33K
Mar 2024 -6.65M 4.20M -1K

DiaMedica Therapeutics alternative data

DiaMedica Therapeutics Inc. (NASDAQ:DMAC): Employee count
Sep 2023 16
Oct 2023 16
Nov 2023 16
Dec 2023 16
Jan 2024 16
Feb 2024 16
Apr 2024 18
May 2024 18
Jun 2024 18
Jul 2024 18

DiaMedica Therapeutics other data

2.27% -5.96%
of DMAC is owned by hedge funds
472.00K -1.23M
shares is hold by hedge funds

DiaMedica Therapeutics Inc. (NASDAQ:DMAC): Insider trades (number of shares)
Period Buy Sel
Nov 2023 20000 0
Jun 2024 2400000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
VON KOCH THOMAS 10 percent owner
Common Shares 1,200,000 $2.5 $3,000,000
Purchase
STAHLBERG JAN 10 percent owner
Common Shares 1,200,000 $2.5 $3,000,000
Purchase
WAMBEKE DAVID J. officer: Chief Business Officer
Voting Common Shares, no par value per share 20,000 $2.46 $49,200
Purchase
VON KOCH THOMAS 10 percent owner
Common Shares 1,470,588 $3.4 $4,999,999
Purchase
GIUFFRE RANDALL MICHAEL director
Voting Common Shares, no par value per share 65,000 $3.91 $254,150
Purchase
PAULS DIETRICH JOHN director, officer: President an..
Voting Common Shares, no par value per share 12,787 $3.91 $49,997
Purchase
SEMBA CHARLES PAULING director
Voting Common Shares, no par value per share 12,787 $3.91 $49,997
Purchase
KELLEN SCOTT officer: CFO and Secretary
Voting Common Shares, no par value per share 10,000 $3.91 $39,100
Purchase
WAMBEKE DAVID J. officer: Chief Business Officer
Voting Common Shares, no par value per share 38,364 $3.91 $150,003
Purchase
PILNIK RICHARD D. director
Voting Common Shares, no par value per share 38,363 $3.91 $149,999
Insider Compensation
Mr. Dietrich John Pauls MBA (1971) Pres, Chief Executive Officer & Director
$687,580
Dr. Harry W. Alcorn Jr., Pharm.D. (1956) Senior Vice President of Clinical Operations $389,930
Mr. Scott B. Kellen C.A. (1965) Chief Financial Officer & Company Sec.
$370,160
Thursday, 14 November 2024
seekingalpha.com
Wednesday, 13 November 2024
businesswire.com
businesswire.com
Wednesday, 6 November 2024
businesswire.com
Monday, 14 October 2024
zacks.com
zacks.com
Wednesday, 9 October 2024
businesswire.com
Wednesday, 4 September 2024
businesswire.com
Thursday, 1 August 2024
zacks.com
Thursday, 11 July 2024
seekingalpha.com
Wednesday, 26 June 2024
businesswire.com
businesswire.com
Saturday, 11 May 2024
Seeking Alpha
Thursday, 18 April 2024
Zacks Investment Research
Monday, 15 April 2024
Zacks Investment Research
Saturday, 23 March 2024
InvestorPlace
Tuesday, 19 March 2024
InvestorPlace
Tuesday, 14 November 2023
Seeking Alpha
Thursday, 31 August 2023
Zacks Investment Research
Tuesday, 15 August 2023
Seeking Alpha
Tuesday, 8 August 2023
Business Wire
Tuesday, 16 May 2023
Seeking Alpha
Monday, 8 May 2023
Business Wire
Wednesday, 29 March 2023
Seeking Alpha
Monday, 20 March 2023
Business Wire
Monday, 13 March 2023
Business Wire
Wednesday, 2 November 2022
Zacks Investment Research
Monday, 31 October 2022
Business Wire
Tuesday, 6 September 2022
Business Wire
Thursday, 11 August 2022
Seeking Alpha
  • What's the price of DiaMedica Therapeutics stock today?

    One share of DiaMedica Therapeutics stock can currently be purchased for approximately $6.17.

  • When is DiaMedica Therapeutics's next earnings date?

    Unfortunately, DiaMedica Therapeutics's (DMAC) next earnings date is currently unknown.

  • Does DiaMedica Therapeutics pay dividends?

    No, DiaMedica Therapeutics does not pay dividends.

  • How much money does DiaMedica Therapeutics make?

    DiaMedica Therapeutics has a market capitalization of 229.41M.

  • What is DiaMedica Therapeutics's stock symbol?

    DiaMedica Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "DMAC".

  • What is DiaMedica Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of DiaMedica Therapeutics?

    Shares of DiaMedica Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are DiaMedica Therapeutics's key executives?

    DiaMedica Therapeutics's management team includes the following people:

    • Mr. Dietrich John Pauls MBA Pres, Chief Executive Officer & Director(age: 54, pay: $687,580)
    • Dr. Harry W. Alcorn Jr., Pharm.D. Senior Vice President of Clinical Operations(age: 69, pay: $389,930)
    • Mr. Scott B. Kellen C.A. Chief Financial Officer & Company Sec.(age: 60, pay: $370,160)
  • How many employees does DiaMedica Therapeutics have?

    As Jul 2024, DiaMedica Therapeutics employs 18 workers.

  • When DiaMedica Therapeutics went public?

    DiaMedica Therapeutics Inc. is publicly traded company for more then 13 years since IPO on 3 Aug 2012.

  • What is DiaMedica Therapeutics's official website?

    The official website for DiaMedica Therapeutics is diamedica.com.

  • Where are DiaMedica Therapeutics's headquarters?

    DiaMedica Therapeutics is headquartered at Two Carlson Parkway, Minneapolis, MN.

  • How can i contact DiaMedica Therapeutics?

    DiaMedica Therapeutics's mailing address is Two Carlson Parkway, Minneapolis, MN and company can be reached via phone at +7 636126755.

DiaMedica Therapeutics company profile:

DiaMedica Therapeutics Inc.

diamedica.com
Exchange:

NASDAQ

Full time employees:

18

Industry:

Biotechnology

Sector:

Healthcare

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Two Carlson Parkway
Minneapolis, MN 55447

CIK: 0001401040
ISIN: CA25253X2077
CUSIP: 25253X207